Search results
Phase 2 topical neuromodulator
- Eirion's lead product ET-01 is a Phase 2 topical neuromodulator product candidate being developed for the treatment of lateral canthal lines (Crow's Feet wrinkles) and primary axillary hyperhidrosis (excessive underarm sweating).
People also ask
What is Eirion's clinical product et-01?
What is Eirion et-02 & ai-09?
Does Eirion treat lateral canthal lines?
How does Eirion et-01 work?
Who is Eirion Therapeutics?
Is Eirion a biopharmaceutical company?
Jul 1, 2024 · ET-02 is the third product currently in development by Eirion. ET-01 topical neuromodulator is in Phase 2 and has been studied in clinical trials with over 750 subjects in aggregate.
Advances in Topical Botulinum Therapy. (PubMed, Dermatol Surg) - "The development of a topical botulinum toxin is appealing because it overcomes multiple disadvantages observed with injectable administration and would likely result in increased clinical use of botulinum toxin.
Oct 17, 2022 · Eirion is currently conducting a Phase 2b double-blind, placebo-controlled clinical trial studying the treatment of lateral canthal lines with topical ET-01. The first cohort of the trial (N=120...
Mar 9, 2021 · Eirion's lead product ET-01 is a Phase 2 topical neuromodulator product candidate being developed for the treatment of lateral canthal lines (Crow's Feet wrinkles) and primary axillary...
Aug 30, 2018 · Clinical Trial to Evaluate ET-01 in Subjects With Lateral Canthal Lines. This study tests an investigational drug formulation called ET-01, botulinum toxin, Type A, topical, in lateral canthal lines (LCL).
Eirion’s exclusive botulinum active pharmaceutical ingredient (API) manufacturer. Botulinum is the active ingredient in Eirion’s lead product candidate ET-01, a topical neuromodulator being developed for row’s Feet wrinkles and primary axillary hyperhidrosis (excessive sweating) that is
Oct 1, 2024 · Eirion’s product candidates include AI-09 liquid injectable neuromodulator, ET-01 topical neuromodulator, and ET-02 small molecule for hair loss and hair greying. In the future, Eirion plans to pursue additional indications that address other major unmet clinical needs for physicians and their patients.
